Celltrion's strategy focuses on developing and manufacturing biosimilars, which are generic versions of biologic drugs. Its current flagship drugs include biosimilars to Remicade, Rituxan ...

Developed by South Korean firm Celltrion (Kosdaq: 068270), with this approval, Yuflyma is now fully interchangeable with the ...

South Korean biopharmaceutical firm Celltrion announced Wednesday that the market share of Remsima SC, the subcutaneous ...

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable ...

INCHEON, South Korea, May 21, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...

In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars.  Biosimilars with an ...

Celltrion announced on the 20th that it has decided to repurchase its own shares worth approximately 100 billion won through its board of directors. The shares to be repurchased this time total ...

South Korean biopharmaceutical firm Celltrion announced Thursday that it has signed a second major deal with one of the top five pharmacy benefit managers in the US, securing private insurance ...

U.S. President Donald Trump signed an executive order aimed at lowering drug prices in the United States to match those in other countries, and local biotechnology corporation Celltrion noted ...

Celltrion’s strategy with its biosimilar of MSD’s Remicade (infliximab), launched in most of Europe around two years ago, was to go for two marketing authorisations and sell rights to one of ...